- Home
- ECPG vs KOD Comparison
ECPG vs KOD Comparison
Compare ECPG & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECPG | KOD |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ECPG | KOD |
|---|---|---|
| Price | $73.48 | $27.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $77.33 | $28.29 |
| AVG Volume (30 Days) | 218.7K | ★ 568.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 287.14 | 32.60 |
| EPS | ★ 10.91 | N/A |
| Revenue | ★ $1,768,802,000.00 | N/A |
| Revenue This Year | $3.63 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $6.78 | ★ N/A |
| Revenue Growth | ★ 34.37 | N/A |
| 52 Week Low | $26.45 | $1.92 |
| 52 Week High | $74.58 | $31.18 |
Technical Indicators
Market Signals| Indicator | ECPG | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 86.09 | 54.58 |
| Support Level | $54.39 | $21.19 |
| Resistance Level | N/A | $29.84 |
| Average True Range (ATR) | 2.99 | 2.01 |
| MACD | 1.69 | 0.30 |
| Stochastic Oscillator | 96.80 | 73.92 |
Price Performance
Historical ComparisonAbout ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.